HMGB1 has already been identified as a therapeutic target in sepsis [14, 50], and several agents that improve survival in sepsis or endotoxemia work by inhibiting secretion of HMGB1 [23, 51–53]. Here, HMGB1 is linked to serum lipopolysaccharide activity.